Loading
NASDAQHealthcareBiotechnology
Latest quote
$13.18
+$0.45 · +3.53%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Latest quote
$13.18
+$0.45 · +3.53%
After-hours
$13.18
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Day range
Current $13.18
52-week range
Current $13.18
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
49
Mixed
Risk
46
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Day range
Current $13.18
52-week range
Current $13.18
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 50M USD | — | — |
| Cost of goods sold | — | 258K USD | — | — | — |
| Gross profit | — | −258K USD | 50M USD | — | — |
| Research and development | 51.52M USD | 38.16M USD | 27.6M USD | 16.89M USD | 22.36M USD |
| Selling, general, and administrative | 16.54M USD | 12.47M USD | 6.32M USD | 5.83M USD | 6.29M USD |
| Operating expenses | 68.06M USD | 50.64M USD | 66.08M USD | 22.72M USD | 28.65M USD |
| Interest income | 8.25M USD | 8.91M USD | 4.61M USD | 761K USD | 77K USD |
| Interest expense | — | — | 208K USD | 388K USD | 332K USD |
| Depreciation and amortization | 323K USD | 258K USD | 195K USD | 329K USD | 325K USD |
| Operating income | −68.06M USD | −50.89M USD | −16.08M USD | −22.72M USD | −28.65M USD |
| Net income | −59.98M USD | −42.26M USD | 22.72M USD | −24.25M USD | −29M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI15.95M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM9.26M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF4.98M0.01%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P Pharmaceuticals ETFXPH2.94M0.64%462.1M USD0.35%$63.63+1.14%
iShares Biotechnology ETFIBB2.88M0.03%10.4B USD0.44%$200.48-1.41%
Vanguard Russell 2000 ETFVTWO2.51M0.01%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA2.04M0.01%21.7B USD0.03%$32.66+0.15%
Dimensional - US Small Cap ETFDFAS1.18M0.00%33.66B USD0.31%$78.10+0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
